The application of siRNA interference technology could improve sensitivity of TFDP3 positively in breast cancer cells to chemotherapy in vitro by down-regulating the expression of TFDP3, so enhancing the effect of chemotherapy and offering important insights into clinical therapy via the integration of chemotherapy with immunotherapy. The gene discussed is TFDP3; the disease is breast carcinoma.